Psychiatric adverse-event signal tracking

What is known

• Pharmacovigilance signals were investigated by EMA and FDA.
• Major published reviews have not established a causal increased risk to date.
• Mood and behavioural changes around any major weight change deserve clinical attention.

What remains uncertain

• Whether sub-populations have specific vulnerability.
• Long-term effects on mood, eating behaviour, and disordered-eating presentations.

Trial limitations

• Pivotal trials are not psychiatry-focused and may under-capture nuanced changes.

FAQs

Have GLP-1 medicines been shown to cause depression or suicidal thoughts?

Pharmacovigilance signals around mood-related and suicidality reports were investigated by both the EMA and FDA. Major published reviews to date have not established a causal increased risk, but this remains an area of active pharmacovigilance rather than a closed question.

Why are regulators still monitoring this if no causal link has been found?

Regulators routinely keep signals under active review even after an initial assessment finds no established causal link, particularly for widely used medicines where rare or delayed effects could still emerge. This reflects the standard operation of pharmacovigilance systems such as MHRA Yellow Card monitoring, not a specific concern unique to this drug class.

Could rapid weight loss itself affect mood, separate from the medicine?

Significant weight and lifestyle change of any kind — through diet, surgery or medicine — can affect mood and eating behaviour, and this is one of the confounding factors regulators and researchers are working to disentangle from a possible drug-specific effect. Long-term effects on mood, eating behaviour and disordered-eating presentations remain an area of ongoing uncertainty.

What should I do if I notice mood changes while on therapy?

Significant mood deterioration, or thoughts of self-harm or suicide, requires urgent qualified clinical help rather than self-management — UK readers can contact NHS 111 or Samaritans on 116 123. Mood or behavioural changes should also be raised with the prescriber managing the treatment.